Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2010

01-04-2010 | Research Article

HE4: a new potential early biomarker for the recurrence of ovarian cancer

Authors: Emanuela Anastasi, Giulia Giovanna Marchei, Valentina Viggiani, Giuseppina Gennarini, Luigi Frati, Maria Gabriella Reale

Published in: Tumor Biology | Issue 2/2010

Login to get access

Abstract

Human epididymis protein 4 (HE4) has recently been described as a new marker for the early diagnosis of ovarian cancer (OC). The objective of this study was to evaluate (a) the expression of HE4 vs. OC mucin CA125 in 32 patients with OC compared to 163 patients with other malignant or benign pathologies (b) HE4 as indicator of the recurrence of the disease in eight patients followed-up for 20 months after OC diagnosis. Serum HE4 and CA 125 levels were determined by ELISA and IRMA, respectively. At diagnosis, the patients with OC demonstrated high levels of both biomarkers with 96.9% sensitivity for HE4 and 85.7% for CA125. In the other pathologies there was 3.7% positivity for HE4 and 21.0% for CA125. The follow-up study showed an increase of HE4 5–8 months before CA125 increment in five of the eight patients, this early expression being strictly associated to a relapse of the disease. In conclusion, this study showed that HE4, compared to CA125, potentially is a better marker for the diagnosis of OC and could be an important early indicator of the recurrence of the disease.
Literature
1.
Ozols RF. Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol. 2002;20:1161–3.PubMed
2.
Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999;80:827–41.CrossRefPubMed
3.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–6.CrossRefPubMed
4.
Haries M, Gore M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol. 2002;3:529–36.CrossRef
5.
Pecorelli S, Creasman WT, Petterson F, Benedet JL, Shepard JH. FIGO annual report on the results of treatment in gynaecological cancer. J Epidemiol Biostat. 1988;3:75–102.
6.
Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005;99:267–77.CrossRefPubMed
7.
Bast Jr RC, Badgwell D, Marquez LR, Rosen D, Liu J, Baggerly KA, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;15:274–81.CrossRefPubMed
8.
Chen DX, Schwartz PE, Li XG, Yang Z. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic mass. Obstet Gynecol. 1988;72:23–7.PubMed
9.
Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol. 2009;142:99–05.PubMed
10.
Tian C, Markman M, Zaino R, Ozols RF, McGuire WP, Muggia FM, et al. CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study. Cancer. 2009;115:1395–403.CrossRefPubMed
11.
Urban N, McIntosh M, Andersen M, Karlan B. Ovarian cancer screening. Hematol Oncol Clin North Am. 2003;17:989–05.CrossRefPubMed
12.
13.
Bingle L, Singleton V, Bingle CD. The putative ovarian tumor marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene. 2002;21:2768–73.CrossRefPubMed
14.
Clauss A, Lilja H, Lundwall A. The evolution of a genetic locus encoding small serine proteinase inhibitors. Biochem Biophys Res Commun. 2005;333:383–9.CrossRefPubMed
15.
Clauss A, Lilja H, Lundwall A. A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acid protein. Biochem J. 2002;368:233–42.CrossRefPubMed
16.
Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65:2162–9.CrossRefPubMed
17.
McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol. 2004;95:9–15.CrossRefPubMed
18.
Galgano MT, Hampton GM, Frierson Jr HF. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19:847–53.PubMed
19.
Moore RG, Brown AK, Miller MC, Kates S, Allard WJ, Verch MS, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402–8.CrossRefPubMed
20.
Moore RG, Brown AK, Miller CM, Badgwell D, Lu Z, Allard J, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrial adenocarcinoma of the uterus. Gynecol Oncol. 2008;108:196–201.CrossRef
21.
Schink JC. Current initial therapy of stage II and IV ovarian cancer: challenges for managed care. Sem Oncol. 1999;26:2–7.
22.
Moorman PG, Calingaert B, Palmieri RT, Iversen ES, Bentley RC, Halabi S, et al. Hormonal risk factors for ovarian. Am J Epidemiol. 2008;167:1059–69.CrossRefPubMed
23.
Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Tuxen TGC, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer. 2005;15:679–91.CrossRefPubMed
24.
Hellerstrom I, Hellerstron KE. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv Exp Med Biol. 2008;622:15–21.CrossRef
25.
Allard J, Somers E, Theil R, Moore RG. Use of a novel biomarker HE4 for monitoring patients with epithelial ovarian cancer. Annual meeting of the ASCO 2008 Abstract.
26.
Carroll JC, Cremin C, Allanson J, Blaine SM, Dorman H, Gibbons CA, et al. Hereditary breast and ovarian cancers. Can Fam Physician. 2008;54:1691–2. Review.PubMed
27.
Fasching PA, Gayther S, Pearce L, Schildkraut JM, Goode E, Thiel F, et al. Role of genetic polymorphisms and ovarian cancer susceptibility. Mol Oncol. 2009;3:171–81.CrossRefPubMed
Metadata
Title
HE4: a new potential early biomarker for the recurrence of ovarian cancer
Authors
Emanuela Anastasi
Giulia Giovanna Marchei
Valentina Viggiani
Giuseppina Gennarini
Luigi Frati
Maria Gabriella Reale
Publication date
01-04-2010
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2010
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-009-0015-y

Other articles of this Issue 2/2010

Tumor Biology 2/2010 Go to the issue

Research Article

Antibody array-based technologies for cancer protein profiling and functional proteomic analyses using serum and tissue specimens

OriginalPaper

Brain-derived neurotrophic factor induces proliferation, migration, and VEGF secretion in human multiple myeloma cells via activation of MEK-ERK and PI3K/AKT signaling

Research Article

Serum micronutrient and antioxidant levels at baseline and the natural history of men with localised prostate cancer on active surveillance

Research Article

Blocking EGFR in the liver improves the tumor-to-liver uptake ratio of radiolabeled EGF

OriginalPaper

Effect of cetuximab treatment in squamous cell carcinomas

Research Article

Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits